Cargando…
EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment
Lung cancer is the global leading cause of cancer-related deaths. A significant portion of lung cancer patients harbor kinase domain mutations in the epidermal growth factor receptor (EGFR). While EGFR tyrosine kinase inhibitors (TKI) effectively shrink tumors harboring mutant EGFR, clinical efficac...
Autores principales: | Zhang, Hongjuan, Zhan, Cheng, Ke, Ji, Xue, Zhiqiang, Zhang, Aiqun, Xu, Kaifeng, Shen, Zhirong, Yu, Lei, Chen, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823112/ https://www.ncbi.nlm.nih.gov/pubmed/26654941 http://dx.doi.org/10.18632/oncotarget.6491 |
Ejemplares similares
-
Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment
por: Zhang, Hongjuan, et al.
Publicado: (2018) -
Hyperthermic intrapleural chemotherapy: an update
por: Campany, Megan E., et al.
Publicado: (2023) -
Abrupt hemodynamic changes accompanying intrapleural hyperthermic chemotherapy: Case series
por: Kim, Hyae-Jin, et al.
Publicado: (2018) -
Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination
por: Yu, Lei, et al.
Publicado: (2013) -
Better effect of intrapleural perfusion with hyperthermic chemotherapy by video‐assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity
por: Cao, Yejun, et al.
Publicado: (2021)